EUCTR2006-005506-32-DK进行中（未招募）不适用
Pain, anxiety and depression in neuropathic and non-neuropathic pain: Effect of monoamine modulation.
Danish Pain Research Center0 个研究点目标入组 86 人开始时间: 2007年1月12日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 86
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients 18-75 years of age.
- •2. Patients with neuropathic pain. Diagnoses: peripheral nerve lesion, polyneuropathy in feet, spinal root compression, and post-herpetic neuralgia.
- •3. Patients with non-neuropathic pain. Diagnosis: fibromyalgia.
- •4. Daily pain present > 6 months.
- •5. Mean weekly pain score > 4 on an 11-point Likert scale the last week of the screening period.
- •6. Treatment with antidepressants (TCA, SSRI, SNRI, MAOI or others), gabapentin, pregabalin, and carbamazepine must be stopped at least two weeks before treatment phase.
- •7. Efficient contraception (women in the fertile age).
- •8. Written and verbal informed consent and letter of authority.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Before the beginning of the study
- •1. Hypersensitivity to the active substance or to any of the excipients in duloxetine.
- •2. Severe renal impairment (creatinine clearance<30 ml/min.)
- •3. Liver disease resulting in hepatic impairment.
- •4. Comcomitant use of nonselective, irreversible or selective, reversible Monoamine Oxidase Inhibitors (MAOIs) within at least 14 days of discontinuing treatment with MAOI. Based on the half-life of duloxetine, at least 5 days should be allowed after stopping duloxetine before starting an MAOI.
- •5. Comcomitant use of fluvoxamine, ciprofloxacin or enoxacine (i.e. potent CYP1A2 inhibitors) since the combination results in elevated plasma concentrations of duloxetine.
- •6. Comcomitant use of serotonergic medicinal products: SSRI´s, TCA´s like clomipramine or amitriptyline, john´s wort (hypericum perforatum), SNRI like venlafaxine or triptans, tramadol, pethidine and tryptofan (risk of serotonine syndrome).
- •7. Comcomitant use of anticoagulants, medical products known to affect platelet function, diuretic medication, alcohol and sedative medicinal products (e.g. benzodiazepines, morphinomimetics, antipsychotics, phenobarbital, sedative antihistamines), flecainide, propafenone and metoprolol (risk of interaction).
- •8. Serious or unstable medical illness (e.g. apoplexy, Alzheimer’s disease, affected platelet function, dehydration, epilepsy, hypertension, haemodialysis, hyponatremia, fructose intolerance, glucose-galactose malabsorption, haemophilia, increased intraocular pressure, ischemic pain, uncontrolled narrow-angle glaucoma, Raynaud´s phenomenon, sucrose-isomaltase insufficiency, and previous case of anaphylactic shock reaction). Confirmed by medical history and, if possible, compared to medical records.
- •9. Current and previous diagnosis of mania, bipolar disorder, psychosis, severe agitation, imminent deliria, suicidal ideation, suicidal behaviour, alcohol or drug dependence (ICD-10). Confirmed by psychiatrical history and, if possible, compared to psychiatrical or medical records.
- •10. Prior participation in a duloxetine study.
- •11. Pregnancy and lactation.
- •After the beginning of the study (discontinuation)
- •1. Development of serious adverse effects or hypersensitivity to the active substance or to any of the excipients in duloxetine.
- •2. Hamilton Depression score > 18 or Major Depression Inventory > 39.9. (Antidepressant medication will be initiated immediately).
- •3. Suicidal ideation and suicidal behaviours (treatment will be initiated immediately).
- •4. Pregnancy.
- •5. Lack of compliance with regard to intake of study medication and diary records.
- •6. Intake of pain and/or antidepressant medication not included in the study.
- •7. The patient cannot co-operate during the examination.
- •8. The patient wishes to leave the study.
研究者
相似试验
招募中
不适用
Assessment of nerve-related pain and altered nerve function in patients with sciaticaumbar radicular painLumbar radicular painNeurological - Other neurological disordersPublic Health - Other public healthACTRN12614000315617Brigitte Tampin90
招募中
1 期
Quantification of neuropathic pain in people with diabetes and physiotherapy treatment in the city of São João da Boa Vista-SPInsulo-dependent diabetes mellitus with neurological complicationsE10.4RBR-4qdjk6Daniella Silva Oggiam
尚未招募
Unknown
Embodiment in neuropathic pain and nociplastic paiMusculoskeletal disorders in knee jointJPRN-UMIN000051711Kio University80
已完成
不适用
Prevalence of Neuropathic Pain in the Patients with Chronic Pain Associated with Spinal Diseases.Chronic pain associated with spinal diseasesJPRN-UMIN000003418The Japanese Society for Spine Surgery and Related Research2,000
尚未招募
Unknown
The effectiveness of adding an additional intervention to a pain management program in people with chronic low back paiChronic low back pain with predominant features of nociceptive or neuropathic painMusculoskeletal - Other muscular and skeletal disordersPhysical Medicine / Rehabilitation - PhysiotherapyACTRN12624000743561a Trobe University184